In Caucasian patients with MS, HLA-DRB1*15:01 is associated with younger age at onset, higher white matter lesion volume, greater brain atrophy and impairment of cognitive function10,18, but its association with clinical course, disease severity, and prognosis is controversial19–23. Here, HLA-DRB1 is linked to myeloid sarcoma.